
News|Articles|June 1, 2007
From the 56th Annual Scientific Session of the American College of Cardiology: EVEREST: Tolvaptan improves symptoms, volume status in patients with acute decompensated HF but offers no long-term impact
The investigational vasopressin receptor antagonist tolvaptan had no long-term impact on clinical events in patients hospitalized with acute decompensated heart failure (ADHF), but the agent did improve symptoms and volume status over the short term, according to results presented at the 56th annual ACC scientific session.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
How California is rewriting the PBM playbook
3
New therapies on the way to lower Lp(a), a cardiovascular risk factor
4
National health expenditures rise 7.2% in 2024, reaching $5.3 trillion
5





















































